Clinical Trials
43 trialsStudy of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Servier
Proton Radiation for Chordomas and Chondrosarcomas
Abramson Cancer Center at Penn Medicine
PRIMHADRON
Hospices Civils de Lyon
ROOT
Taproot Health
Grade 2 Chondrosarcoma Treated by Intralesional Curettage: Follow-up vs Resection
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
TopAlliance Biosciences
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Osteosarcoma
Stanford University
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Emerald Clinical Inc.
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
AIAC
Peking University People's Hospital
MACIST
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Trial of Dasatinib in Advanced Sarcomas
Sarcoma Alliance for Research through Collaboration
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
National Cancer Institute (NCI)
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
Wake Forest University Health Sciences
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
Peking University People's Hospital
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
AEterna Zentaris
CH01
University of Florida
Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine
Massachusetts General Hospital
High-dose ICE With Amifostine
Dana-Farber Cancer Institute
CONDRO1
Istituto Ortopedico Rizzoli
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
University of Miami
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Celldex Therapeutics
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
National Cancer Institute (NCI)
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Alanosine in Treating Patients With Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
Memorial Sloan Kettering Cancer Center
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
National Cancer Institute (NCI)
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
Infinity Pharmaceuticals, Inc.
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma Alliance for Research through Collaboration
S0344 Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone
SWOG Cancer Research Network
S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma
SWOG Cancer Research Network
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center